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Abstract 
Cancer inducible molecular chaperone HSP90 is of great importance as an anticancer target. 
Proteomic analysis showed that inhibiting HSP90 by the geldanamycin derivative, 17-AAG elevated 
the expression of the co-chaperone Hsp70. In this study we used HSP90 selective inhibitor 
17-AAG and HSP70/90 dual inhibitor, VER155008 (VER) in U87-MG glioma cells. miRNAs mi-
croarray technology was used to evaluate the efficacy of these inhibitory drugs compared with 
temozolomide (TMZ), used as a standard treatment for glioma. Microarrays data identified 154 
differentially expressed miRNAs using stringent or unstringent parameters. 16 miRNAs were 
overlapped between treatments, 13 upregulated and one downregulated miRNA were overlapped 
between TMZ and VER. The miRNA target prediction software was used for these overlapped 
miRNAs and identified 6 of the 13 upregulated miRNAs target methyltransferase genes. The IC50, 
together with Akt and HSP70 and 90 protein level data favour VER and TMZ to 17-AAG, however 
due to the selectivity of VER to cancer cells as a potent antichaperon, it may be more favourable to 
the standard TMZ. 
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Introduction 
Heat Shock proteins (HSPs) are established 
therapeutic targets for various disease such as Alz-
heimer’s, Huntington’s, cardiovascular and cancer (1). 
HSPs or stress proteins are highly conserved molecu-
lar chaperones that assist folding of misfolded pro-
teins (2,3). The co-chaperones HSP90 and HSP70 are 
important members of the HSP family that are impli-
cated in cellular processes by chaperoning oncogenic 
client proteins like Ras, p53 and Akt (4). Akt, also 
known as protein kinase B (PKB), is 
a serine/threonine-specific protein kinase that plays a 
key role in multiple cellular processes such as glucose 
metabolism, apoptosis, cell proliferation, transcrip-
tion and cell migration. It is known to require HSP90 
chaperone for proper folding, maturation and activi-
ty. 
Although inhibiting HSP90 by the antibiotic 
geldanamycin derivative 17-allylamino-17-demetho-
xygeldanamycin (17-AAG), currently in phase III trial 
(5-7), it causes destabilization of its client proteins and 
induces cell apoptosis, proteomic analysis showed an 
elevated HSP70 expression compensating for the in-
hibition of HSP90 (8). Thus, in order to enhance the 
efficacy of treatment, both HSP90 and HSP70 need to 
be inhibited.  
In this study 17-AAG was used to inhibit HSP90 
activity, while VER155008 (VER) was used to inhibit 
both HSP70/90 in U87-MG glioma cells. VER is an 
adenosine-derived compound that is selective to-
wards HSP70, however it’s selectivity is not exclusive 
since it also binds to HSP90β (9). The standard treat-
ment for glioblastoma is temozolomide (TMZ) and in 
this study was used as a positive control. 
miRNA microarrays is a powerful tool that has 
facilitated our understanding of biological roles and 
offers a more detailed profile for comparing different 
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treatments. This method was used to determine if 
there is a correlation between treatment efficacies.  
miRNAs are evolutionarily conserved endoge-
nously expressed small non-coding RNAs of 19-22 
nucleotides in length that direct Argonaute proteins 
to bind and repress complementary mRNA targets 
(10,11). Over 60% of protein-coding genes are regu-
lated by miRNA, which have diverse roles in cellular 
processes such as proliferation, apoptosis and cancer 
development (12,13). 
Materials and methods 
Normal Cell Culture Conditions 
The human brain tumour cell lines 1321N1 (as-
trocytoma), GOS-3 (mixed astro-oligodendroglioma) 
and U87-MG (glioblastoma multiforme) were pur-
chased from the European Collection of Cell Cultures 
(ECCAC, UK) and Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DMSZ, Germa-
ny). U87-MG cells were cultured in Eagle’s Minimum 
Essential Medium (EMEM) (Lonza, UK) and GOS-3 
and 1321N1 cells in Dulbecco’s modified Eagle’s me-
dium (DMEM) (Sigma, UK). This cell culture medium 
was supplemented with 10% Fetal Bovine Serum 
(Lonza, UK), 2mM L-glutamine (Lonza, UK), 1% v/v 
non-essential amino acids (Lonza, UK), and 1mM so-
dium pyruvate (Lonza, UK). The normal brain cell 
line Normal Human Astrocytes (NHA) was used as a 
control. Cells were maintained in a humidified incu-
bator at 37°C with 5% CO2 and filtered air. All cells 
were passaged to 70-80% confluence and restricted to 
5-7 passages.  
Drug Preparation 
The 2 mM stock concentrations of 17-AAG 
(Invivogen, UK) and VER (Tocris, UK) and 10 mM 
stock concentration of TMZ (Provided by Royal 
Preston Hospital, UK) were reconstituted in DMSO. 
Steps were followed to ensure that the final concen-
tration of DMSO in the cell culture experiments did 
not exceed 0.08%. All compounds were purchased in 
pure powder form. 
Cell viability and Chemosensitivity assay 
The glioma cells 1321N1, GOS-3 and U87-MG 
were seeded at a density of 2000 cells/well in 96-well 
plates in triplicate for 24 h. After which, they were 
incubated for further 48 h at various concentrations of 
drug (TMZ, 17-AAG and VER). The untreated cells 
were used as control for each cell line. The inhibitory 
concentrations (IC50) of the drugs were determined 
using CellTiter-Glo luminescent cell viability assay 
(Promega, UK) using Tecan GENios Pros (Tecan 
Austria) (14,15). 
In order to determine the chemosensitivity of all 
three glioma cell lines towards the inhibitory com-
pounds, cells were treated with the IC50 concentra-
tions of 17-AAG, VER and TMZ (Table 1). After 48 h 
treatment, the luminescent signals were measured 
following the standard protocol (14). 
 
Table 1: Inhibitory concentrations of the pharmacological 
compounds for 1321N1, GOS-3 and U87-MG glioma cell lines.  
Cell lines TMZ (μM) 17-AAG (nM) VER (μM) 
1321N1 135 ± 6 100 ± 2 12 ± 4 
GOS-3 147 ± 11 100 ± 9 12 ± 9 
U87-MG 180 ± 3 80 ± 1 13 ± 1 
(n=3, ±S.D) 
 
Drug treatment for microarray analysis 
U87-MG cells were seeded in 75 cm2 culture 
flasks 24 h prior to treatment. Cells were treated with 
IC50 concentrations of the three drugs TMZ, 17-AAG 
and VER. The untreated cells (control) and drug 
treated cells were harvested after 48 h and stored in 
RNA protected cell reagent (Qiagen, UK) at -80°C. 
The cell samples were then used for microRNA anal-
ysis (IMGM Laboratories, Germany). 
miRNA Microarray analysis 
Total RNA was isolated using the miRNeasy 
Mini Kit (Qiagen) according to manufacturer’s in-
structions. Aliquots of total RNA samples were used 
to determine the RNA concentration and purity using 
the Nano Drop ND-1000 spectral photometer 
(peqlab). RNA integrity was assessed by capillary 
electrophoresis using RNA 6000 Nano LabChip Kits 
and Bioanalyzer 2100 (Agilent Technologies). As 
recommended, total RNA samples with RNA integ-
rity number (RIN) value ≥ 7.5 was used for the label-
ling the reaction to achieve high quality cRNA.   
Labelling and Microarray hybridization 
The samples containing 100 ng of total RNA 
were spiked with in vitro synthesised oligonucleotides 
prior to labelling (MicroRNA Spike-in Kit, Agilent 
technologies). Sample’s total RNA was then intro-
duced into ligation-based labelling reaction. Accord-
ing to Agilent’s miRNA Complete Labelling and Hyb 
Kit protocol, total RNA was treated with Calf Intesti-
nal Alkaline Phosphatase (CIP) followed by labelling 
of dephosphorylated RNA using T4 RNA Ligase. This 
method involves ligation of one Cyanine 3-pCp mol-
ecule to the 3' end of a RNA molecule with greater 
than 90% efficiency, cyanine 3-pCp labels and hy-
bridizes mature miRNA. The total amount of each 
cyanine 3-pCp-labeled miRNA sample was then pre-
pared for one-color Hybridization. The Labelled 
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miRNA samples were then incubated at 55°C for 20 h 
on Agilent Human miRNA Microarrays Release 19.0 
in 8 × 60K format (AMADID 046064). The fluorescent 
signals were detected on an Agilent DNA microarray 
scanner and the images were extracted using the 
Feature Extraction software version 10.7.3.1.  
Bioinformatics analysis  
Normalization, quality control, statistical data 
analysis, miRNA annotation and visualization was 
carried out using statistical software such as Feature 
Extraction 10.7.3.1, GeneSpring GX 12.5 and Spotfire 
Decision Site 9.1.2. The raw data was normalised us-
ing Quantile Normalisation and similarities within 
and between differentially expressed miRNAs sam-
ples were evaluated using Pearson’s correlation coef-
ficient (r) and was also visualised using a correlation 
heat map. The application of Benjamini and Hochberg 
False Discovery Rate (FDR) adjustment was utilized 
to avoid multiple testing errors and estimated the 
corrected significance level (p value) (16). Fold change 
(FC) was calculated to determine differential expres-
sion of samples. PCA (Principle component analysis) 
plot, Dot plot and Hierarchical clustering were ana-
lysed for comparison of differential groups of data 
subsets and clustering of similar expressions. 
miRNA Target prediction 
Target predicting databases among which Target 
Scan Human 6.2, DIANA-microT, miRBD miRBase 
V18 and miRo- the miR ontology were used for pre-
dicting potential target genes. In order to reduce false 
target genes obtained, mRNA data sets of predicted 
targets were further filtered on the basis of 
co-predicted targets from different algorithms (17-19). 
Protein extraction and Akt/ PKB kinase activ-
ity assay 
The CelLytic™ M Cell Lysis Reagent (Sigma, 
UK) was used together with supplements of a prote-
ase inhibitor cocktail for collection and lysis of the 
cells (14). Total protein was isolated from the re-
maining cell debris by centrifugation at 13,000 rpm for 
15 min. The protein concentration was determined 
using the Bradford protein assay. The non-radioactive 
Akt/PKB kinase activity assay was used to measure 
Akt/PKB kinase activity in the solution phase (Assay 
Designs, UK; Cat No. EKS-400A). From the total pro-
tein isolated as described above, 10 µg of protein from 
each sample were used to perform the Akt kinase 
assay (5). 
Hsp70/90 ELISA assay 
HSP70 ELISA assay (Assay Designs, UK; 
ADI-EKS-700B) and HSP90 ELISA assay (Assay De-
signs, UK; ADI-EKS-895) were used to determine and 
quantitate inducible HSP70 and 90 activities in the cell 
lysate samples, respectively. From the total protein 
isolated using 106-107 cells, 500 ng/ml of cell lysate 
from each sample was used to perform HSP70 and 90 
assay according to the manufacturer’s instructions.  
Statistical analysis 
The cell viability and chemo sensitivity data was 
analysed using PASW statistical 18 packages and 
Graph pad Prism for One-Sample Students T-test and 
Paired-Sample T-test. The data presented are the 
mean of three independent experiments ±SD (stand-
ard deviation) and the values of *p < 0.05 and **p < 
0.001 were considered to be statistically significant. 
Results  
The mRNA transcription levels of hsp90α (the 
induced subunit of hsp90) and hsp70 were measured 
using qRT-PCR in glioma and NHA cell lines. Both 
glioma and NHA cell lines showed various levels of 
hsp90α transcription. Glioma cell lines transcribed 
hsp90α at induced levels in comparison to hsp70. Low 
constitutive hsp90α and no hsp70 mRNAs were de-
tected in the normal NHA cells. Thus, only glioma cell 
lines were used for further analysis while the normal 
cell line was exempted (Fig.1). 
Akt/PKB kinase acts as client proteins for the 
HSP90-HSP70 complex, playing an essential role in 
stabilising and in the activation of the multiprotein 
complex. Hence HSP70 and HSP90 activities were 
assessed by measuring the Akt/PKB kinase levels 
(Table 2). 
The data illustrates a significant inhibitory effect 
demonstrated by the IC50 of the three drugs on the 
U87-MG cells and therefore the U87-MG cells line was 
used for further studies. 
 
 
Figure 1: hsp90α and hsp70 gene transcription level: Gene transcriptional 
levels compared normal cell lines (NHA) to glioma cell lines (1321N1, 
GOS-3 and U87-MG). Data represented (n=3, ±S.D). 
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Table 2: Akt Kinase activity assay: Akt kinase activity levels in 
glioma cells before and after treatment. Untreated cells were used 
as controls (n=3, ±S.D)  
Cell lines Kinase activity for 1 μg Protein 
1321N1 84 ± 37 
1321N1 TMZ 22 ± 3 
1321N1 17-AAG 7 ± 3 
1321N1 VER 52 ± 4 
GOS-3 201 ± 7 
GOS-3 TMZ 69 ± 4 
GOS-3 17-AAG 82 ± 6 
GOS-3 VER 156 ± 5 
U87-MG 121 ±15 
U87-MG TMZ 17 ± 3 
U87-MG 17-AAG 32 ± 5 
U87-MG VER 20 ± 2 
 
 
U87-MG cells treated with TMZ, 17-AAG and 
VER were subjected to miRNA microarrays and the 
untreated U87-MG cells were used as a control.  
The identification of significantly differentially 
expressed miRNAs on the three pair wise compari-
sons is presented in Table 3.  
The magnitude of involving both up and down 
regulation of miRNAs from U87-MG cells treated 
with TMZ, 17-AAG and VER compared with the un-
treated cells as control are presented in Table 4.  
miRNAs are known to regulate the expression of 
several distinct mRNA targets. Examples of the target 
genes of differentially expressing miRNA were de-
termined using different target predicting algorithms 
such as Target Scan Human 6.2, DIANA-microT and 
miRBD miRBase V18. The miRNAs were overlapped 
and genes predicted with two or more algorithms 
were used to avoid false targeting (Table 5).  
HSP70 and 90 protein levels were measured 
using specific Elisa kits for treated and untreated cells 
(Table 6). 
 
Table 3: Summary of the number of significantly up and down 
regulated miRNAs from U87-MG cells treated with TMZ, 17-AAG 
and VER compared with the untreated cells as control.  
Comparison p(Corrected) ≤ 0.05  
FC ≥ 2 
p≤ 0.05  
FC ≥ 2 
Up Down Up Down 
TMZ Vs Control 0 0 19 7 
17-AAG Vs Control 0 0 4 1 
VER Vs Control 9 4 61 62 
FC is fold change. The uncorrected p value uses non-stringent filtering. The multi-
ple testing errors are not taken into account. 
 
Table 4: Differential miRNAs expression 
TMZ vs control 17-AAG vs control VER vs control 
Up FC Up  FC Up  FC Down FC 
hsa-miR-215  164.61 hsa-miR-3161 29.29 hsa-let-7e-5p 2.03 hsa-miR-10b-3p -31.15 
hsa-miR-194-5p 138.93 hsa-miR-557 18.90 hsa-let-7g-5p 2.26 hsa-miR-1225-5p -2.59 
hsa-miR-550a-3p 64.87 hsa-miR-3692-5p 17.71 hsa-miR-103a-3p 2.62 hsa-miR-1227-5p -2.94 
hsa-miR-769-5p 63.60 hsa-miR-664b-5p 17.18 hsa-miR-107 2.21 hsa-miR-1234-3p -2.53 
hsa-miR-744-5p 63.11     hsa-miR-1180 23.93 hsa-miR-1234-5p -2.15 
hsa-miR-449a 61.97     hsa-miR-125a-5p 2.62 hsa-miR-135a-3p -5.36 
hsa-miR-101-3p 49.19     hsa-miR-128 2.55 hsa-miR-138-2-3p -3.19 
hsa-miR-200c-3p 33.26     hsa-miR-1285-3p 2.26 hsa-miR-139-3p -3.60 
hsa-miR-652-3p 29.38     hsa-miR-1306-3p 2.15 hsa-miR-1469 -10.14 
hsa-miR-7-1-3p 23.49   hsa-miR-148b-3p 2.32 hsa-miR-1587 -2.24 
hsa-miR-4521 23.13   hsa-miR-152 2.84 hsa-miR-1915-3p -2.59 
hsa-miR-500a-3p 19.00   hsa-miR-185-5p 2.22 hsa-miR-197-5p -2.33 
hsa-miR-4758-3p 18.65   hsa-miR-194-5p 62.83 hsa-miR-2861 -2.90 
hsa-miR-557 17.92   hsa-miR-1972 2.03 hsa-miR-3137 -2.11 
hsa-miR-382-5p 16.00   hsa-miR-204-5p 2.02 hsa-miR-3188 -2.25 
hsa-miR-192-5p 4.94   hsa-miR-215 60.74 hsa-miR-3196 -3.11 
hsa-miR-324-5p 2.10   hsa-miR-23b-3p 2.18 hsa-miR-3663-3p -2.02 
hsa-miR-331-3p 2.08   hsa-miR-26a-5p 2.20 hsa-miR-371b-5p -3.13 
hsa-miR-148b-3p 2.03   hsa-miR-30c-2-3p 2.19 hsa-miR-3940-5p -2.01 
      hsa-miR-30d-5p 2.03 hsa-miR-4428 -3.08 
      hsa-miR-30e-3p 2.05 hsa-miR-4430 -3.13 
      hsa-miR-3152-3p 2.39 hsa-miR-4446-3p -2.63 
    hsa-miR-3158-5p 2.16 hsa-miR-4462 -2.58 
    hsa-miR-3161 2.18 hsa-miR-4478 -2.23 
Down  FC Down FC hsa-miR-324-5p 2.12 hsa-miR-4505 -2.48 
hsa-miR-3654 -72.55 hsa-miR-345-5p -2.03 hsa-miR-342-3p 2.71 hsa-miR-4507 -2.08 
hsa-miR-335-3p -70.32   hsa-miR-3617-5p 61.40 hsa-miR-4515 -2.30 
hsa-miR-3620-5p -49.68   hsa-miR-374b-5p 2.11 hsa-miR-4530 -2.89 
hsa-miR-431-3p -41.62   hsa-miR-379-5p 54.30 hsa-miR-4532 -2.02 
hsa-miR-4636 -32.06   hsa-miR-382-5p 57.71 hsa-miR-4538 -2.04 
hsa-miR-193a-5p -2.20   hsa-miR-432-5p 2.15 hsa-miR-4634 -3.26 
hsa-miR-4697-5p -2.06   hsa-miR-4443 3.03 hsa-miR-4636 -33.24 
    hsa-miR-4458 92.84 hsa-miR-4647 -26.47 
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    hsa-miR-4484 3.37 hsa-miR-4656 -2.26 
    hsa-miR-449a 76.65 hsa-miR-4665-5p -2.81 
    hsa-miR-449c-5p 43.48 hsa-miR-4721 -2.10 
    hsa-miR-4506 42.65 hsa-miR-4728-5p -2.03 
    hsa-miR-4521 55.63 hsa-miR-4739 -2.04 
    hsa-miR-4710 39.07 hsa-miR-4741 -2.47 
    hsa-miR-4726-5p 2.16 hsa-miR-4767 -42.21 
    hsa-miR-486-5p 23.39 hsa-miR-4787-3p -36.67 
    hsa-miR-493-5p 18.18 hsa-miR-4787-5p -2.66 
    hsa-miR-497-5p 2.01 hsa-miR-5001-5p -2.42 
    hsa-miR-498 2.11 hsa-miR-5006-5p -2.07 
    hsa-miR-500a-3p 17.46 hsa-miR-503-5p -51.76 
    hsa-miR-5010-5p 17.79 hsa-miR-513a-5p -3.22 
    hsa-miR-502-3p 32.91 hsa-miR-513b -3.27 
    hsa-miR-5196-5p 37.43 hsa-miR-513c-5p -3.49 
    hsa-miR-520c-3p 2.24 hsa-miR-548q -126.10 
    hsa-miR-532-3p 2.71 hsa-miR-5585-3p -95.73 
      hsa-miR-550a-3p 81.24 hsa-miR-575 -3.96 
      hsa-miR-6134 2.23 hsa-miR-6068 -3.95 
    hsa-miR-652-3p 40.79 hsa-miR-6089 -2.57 
    hsa-miR-7-1-3p 61.35 hsa-miR-6090 -2.01 
    hsa-miR-744-5p 43.32 hsa-miR-6125 -3.06 
    hsa-miR-758-5p 3.04 hsa-miR-638 -2.83 
    hsa-miR-769-5p 48.11 hsa-miR-650 -15.32 
    hsa-miR-885-5p 28.68 hsa-miR-6722-3p -2.22 
    hsa-miR-9-5p 2.38 hsa-miR-718 -8.71 
    hsa-miR-98-5p 2.63 hsa-miR-921 -5.53 
        hsa-miR-940 -3.82 
 
Table 5: The 14 overlapped miRNA between TMZ and VER, 13 upregulated and one downregulated with their fold change and the 
predicated genes they control.  
Upregulated miRNA TMZ vs 
control 
FC 
VER vs 
control 
FC 
Gene  
hsa-miR-215 C* 
 
 
164.61 
 
 
60.74 
 
Alcam 
Activate leukocyte cell adhesion molecule 
CD166 antigen is transmembrane glycoprotein that in humans it is 
encoded by the ALCAM gene. CD166 has also been used as a potential 
cancer stem cell marker.  
hsa-miR-194-5p 
 
 
 
 
 
 
 
 
 
138.93 
 
 
 
 
 
 
 
 
 
62.83 
 
 
 
 
 
 
 
 
 
Dnmt3a 
DNA methyl transferase 3A 
 
 
This gene encodes a DNA methyltransferase which is thought to 
function in epigenetic CPG methylation, rather than maintenance 
methylation. 
 
TRD1 tRNA aspartic acid methyltransfer-
ase1 
 
This gene encodes a protein responsible for the methylation of aspar-
tic acid transfer RNA, specifically at the cytosine-38 residue in the 
anticodon loop. This enzyme also possesses residual 
DNA-(cytosine-C5) methyltransferase activity.  
hsa-miR-550a-3p 
 
 
 
64.87 
 
 
 
81.24 
 
 
 
Dnmt3a 
DNA methyl transferase 3A 
This gene encodes a DNA methyltransferase which is thought to 
function in epigenetic CPG methylation, rather than maintenance 
methylation. 
hsa-miR-769-5p C* 
 
 
 
 
 
63.60 
 
 
 
 
 
48.11 
 
 
 
 
 
TRD1 tRNA aspartic acid methyltransfer-
ase 1 
 
This gene encodes a protein responsible for the methylation of aspar-
tic acid transfer RNA, specifically at the cytosine-38 residue in the 
anticodon loop. This enzyme also possesses residual 
DNA-(cytosine-C5) methyltransferase activity.  
hsa-miR-744-5p C* 
 
63.11 
 
43.32 DNAJC16  
 
HSP40, subfamily C, member 16 
hsa-miR-449a 
 
 
 
61.97 
 
 
 
76.65 
 
 
 
Cyclin E2  Distinct functions of cyclin in development and cancer 
Cyclin Dependent Kinase (Cdk6) Knockdown of cdk6 enhances glioma sensitivity of chemotherapy. 
hsa-miR-652-3p 
 
 
29.38 
 
 
40.79 
 
 
TRMT5  
tRNA methyltransferase 5 
TRMT5 posttranscriptionally methylates the N1 position of 
guanosine-37 (G37) in selected tRNAs using S-adenosyl methio-
nine  
hsa-miR-7-1-3p 
 
 
23.49 
 
 
61.35 
 
 
TARDBP 
TAR DNA binding protein 
 
Overexpression caused partially P53 dependent G2/M arrest and P53 
independent cell death 
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Dnmt3a 
DNA methyl transferase 3A 
This gene encodes a DNA methyltransferase which is thought to 
function in epigenetic CPG methylation, rather than maintenance 
methylation. 
hsa-miR-4521 
 
23.13 
 
55.63 
 
GABARAPL2 
 
GABA(A) receptor-associated  
protein-like 2 
hsa-miR-500a-3p C* 
 
 
19.00 
 
 
17.46 FBXW7 F-box and WD repeat domain 
contain 7, E3 ubiquitin protein ligase  
FBXW7 beta form is suppressed in human glioma cells 
hsa-miR-382-5p 16.00 57.71 TOP1 
topoisomerase (DNA) I 
DNA topoisomerase controls and alters the topologic states of 
DNA during transcription.  
hsa-miR-324-5p 
 
2.10 
 
 
2.12 
 
MGAT3 Mannose (beta-1,4)-glycoprotein 
beta-1,4-acetylglucosaminyltransferase 
Transfection of the gene in glioma cells effect glycoconjugate and 
enhance cell death 
hsa-miR-148b-3p 
 
 
 
 
 
2.03 
 
 
 
 
 
2.32 
 
 
 
Dnmt3B 
DNA methyl transferase 3 beta 
DNA (cytosine-5-)-methyltransferase 1 has a role in the establishment 
and regulation of tissue-specific patterns of methylated cytosine 
residues. Aberrant methylation patterns are associated with certain 
human tumours. 
downregulated 
miRNA 
    
hsa-miR-4636 
 
-32.06 
 
-33.24 
 
TXNDC5 
thioredoxin domain containing 5 (en-
doplasmic reticulum) 
This gene encodes a protein-disulfide isomerase. Its expression is 
induced by hypoxia and its role may be to protect hypoxic cells 
from apoptosis 
C* Corrected p value 
 
 
Table 6: HSP70 and 90 activity assays: HSP70 and 90 activity 
levels in U87-MG cells before (control) and after treatment.  
 HSP70 activity for 0.5 µg 
protein 
HSP90 activity for 0.5 µg 
protein 
Control 77 ± 11 558 ± 62 
TMZ 67 ± 17 92 ± 12 
17-AAG 77 ± 9 322 ± 36 
VER 62 ± 6 198 ± 16 
(n=3, ±S.D) 
 
Discussion 
The co-chaperones, HSP70 and 90 proteins are 
key mediators in regulating cell survival by affecting 
proliferating pathways, cell cycle progression and 
apoptosis. Due to their low constitutive and highly 
induced cancer expression levels, HSP70 and 90 
proteins are considered valid anti-glioma targets. 
The mRNA levels of hsp70 and 90 were initially 
determined in three glioma cell lines, namely; 1321N1, 
GOS-3 and U87-MG and compared to the normal 
human astrocyte cell line, NHA. Although, the glioma 
cell lines showed induced transcription levels of both 
genes, hsp90 is more upregulated than hsp70. Because 
hsp90 was marginally transcribed at a constitutive 
level and no hsp70 mRNAs were detected in the nor-
mal cell line NHA, the investigation focussed only on 
the three glioma cell lines.  
The glioma cell lines were subjected to the IC50 
using two different treatments, VER and 17-AAG to 
inhibit HSP70 and 90 expressions, respectively. The 
cell lines treated with glioma chemotherapeutic drug 
TMZ were used as positive controls, while the un-
treated cell lines were used as negative controls. The 
average IC50 for 17-AAG, TMZ and VER in the three 
glioma cell lines were 0.09, 153 and 13 μM, respec-
tively, suggesting that the antichaperones are more 
potent compounds than TMZ. 
HSP70/90 proteins stabilised with client proteins 
such as Akt/PKB kinase behave as oncoproteins 
suppressing cell proliferation and regulating apopto-
sis of malignant cells (20). Hence, measuring Akt ki-
nase activities in glioma cell lines can be indicative of 
HSP70/90 activity. Akt/PKB kinase activities were 
measured using ELISA kits in treated and untreated 
cells. Akt kinase activity in 1321N1 cells treated with 
TMZ, 17-AAG and VER were reduced to 26, 8 and 62 
%, respectively. GOS-3 cells were reduced upon 
treatment to 34, 41 and 78 %, respectively, while 
U87-MG cells showed a reduction to 14, 26 and 17 %, 
respectively. In all three cell lines, Akt kinase was 
reduced to varying degrees on treatment with TMZ, 
17-AAG and VER.  
Interestingly TMZ inhibited Akt kinase at vary-
ing levels in the three cell lines used in this study.  
Although there is a significant Akt kinase inhi-
bition following treatment with VER and 17-AAG in 
all three cell lines, U87-MG showed almost equal in-
hibition between the two treatments. Based on this 
data and previous findings from our lab, the U87-MG 
cell line was employed for further investigations.  
Inhibiting HSP90 protein highly induced HSP70 
and subsequently compromised the treatment efficacy 
(8), furthermore, blocking both HSP70 and 90 using 
pharmacological inhibitors assisted treatment (21).  
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In this study miRNA profiling was used in order 
to assess the treatment between 17-AAG and VER as 
HSP90 and 70 inhibitors, respectively in glioma cells 
in comparison to TMZ. 
U87-MG cells were treated with the IC50 of 
17-AAG, VER and TMZ. The differentially transcribed 
miRNA in each group of the treated cells were com-
pared to the untreated cells. The microarrays were 
carried out in duplication for accuracy. Differential 
miRNA expressions were assessed for three pair wise 
comparisons. Stringent filtering delivered very few 
miRNAs in cells treated with VER (9 upregulated and 
4 downregulated), thus, non-stringent filtering was 
applied to the data (uncorrected) and resulted in the 
identification of 154 miRNAs, 84 of which were up-
regulated. The cells treated with VER were the only 
cohort that were subjected to stringent filtering where 
multiple testing errors were taken into account and 
false discovery rate was controlled and limited to a 
maximum level of 5%. 
17-AAG was the first geldanamycin analogue to 
enter clinical trials (22). Previously we demonstrated 
the effectiveness of 17-AAG using U87-MG [5,14]. 
Interestingly in this study, 17-AAG influenced miR-
NA expression profile by the upregulation of four and 
downregulation of one miRNA, however, the only 
treatment that showed corrected data that stands 
against the stringent filter was the VER treated cells.  
The data showed overlapping of 16 miRNAs 
between treatments, 14 of the 16 overlapped miRNAs 
were shared between TMZ and VER treated cells. Of 
the 14 overlapped miRNAs, 13 that upregulated were 
further analysed for gene prediction using software 
packages to include; Target Scan Human 6.2, 
DIANA-microT, miRBD miRBase V18 and miRo- the 
miR ontology. 
Although miRNA may regulate more than one 
gene, we limited our miRNA gene prediction study to 
those with top scorer prediction or validated.  
miR-215 was upregulated by 165 and 61 fold in 
cells treated with TMZ and VER, respectively, and 
below the fold change detection in cells treated with 
17-AAG. It has been reported that miR-215 upregula-
tion leads to down regulation of Alcam in the human 
gastric epithelial cell line (HFE145) (23). 
miR-449 regulates Cyclin E2 and Cyclin De-
pendent Kinase 6 (Cdk 6) by inhibiting cell progres-
sion activity in cancer cells and also indirectly regu-
lates Cdk4, as its 3’UTR is dissimilar to the miR-449 
sequence (24). miR-744-5p targets DNAJ, also known 
as HSP40 a molecular chaperone protein. This family 
of proteins contain a 70 amino acid consensus se-
quence known as the J domain which is known to 
interact with HSP70. DNAJC16 belongs to the evolu-
tionarily conserved DNAJ/HSP40 family of proteins 
(25). 
miR-194-5p was upregulated by 139 and 63 fold 
in cells treated with TMZ and VER, respectively and 
has been identified on Chromosome 1 and targets 
Dnmt3a (26). Interestingly, miR-550a-3p, miR-7-1-3p 
also targets Dnmt3a and miR-148b-3p targets Dnmt3b. 
miR-194-3p and miR-769-5p target TRD1 tRNA as-
partic acid methyltransferase1. miR652-3p targets 
TRMT5 tRNA methyltransferase 5.  
The human genome contains hundreds of 
miRNAs and each miRNA can repress hundreds of 
genes, regulating almost every cellular process. Gene 
repressing or silencing may occur either via mRNA 
degradation or preventing mRNA from being trans-
lated (27). If there is a complete complementation 
between the miRNA and the target mRNA sequence, 
Ago2 can cleave the mRNA and lead to mRNA deg-
radation. However, if there is incomplete comple-
mentation, the silencing is achieved by preventing 
translation (28).  
As previously listed, 6 of 13 upregulated over-
lapped miRNAs target various types of methyltrans-
ferases, suggesting that TMZ and VER treatments 
downregulate methyation processes through en-
hanced corresponding miRNAs, albeit via different 
mechanisms.  
HSP70 or HSP1A1 is a ubiquitous molecular 
chaperone that contributes to cancer cell survival via 
anti-apoptotic functions. It functions in various bio-
logical processes including modulation of polypep-
tide folding, protein degradation, translocation across 
membranes, and protein-protein interactions. HSP70 
is post-translationally modified by phosphorylation, 
ubiquitination and glycosylation. Enhanced HSP70 
methylation is detected in various types of human 
cancer although the methylation was barely detecta-
ble in the corresponding non-neoplastic tissues. These 
findings demonstrate a crucial role for HSP70 meth-
ylation in human carcinogenesis (29).  
VER is a potent inhibitor of Hsp70 which has 
been shown to inhibit HSP70 as well as heat shock 
cognate 71 kDa protein (Hsc70) and 78 kDa glu-
cose-regulated protein (Grp78). It is known to have an 
affinity to bind to HSP90β to a lesser extent (30). X-ray 
crystallography analysis reveals that VER binds to the 
ATPase pocket of Hsp70 leading to the inhibition of 
the intrinsic ATPase activity of HSP70 and subsequent 
downstream events. VER binding to HSP70 could 
inhibit methylation via negative feedback or 
post-translational processes triggering enhanced se-
lective miRNAs. 
On the other hand, the therapeutic benefit of 
TMZ depends on its ability to alkyl-
ate/methylate DNA, which, most often occurs at the 
N-7 or O-6 positions of guanine residues. This meth-
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ylation damages the DNA and triggers the death of 
tumour cells (31). The interaction between c-Myc and 
Dnmt3a would then activate DNA methyltransferase 
which increases local de novo DNA methylation in the 
CpG islands of the MGMT promoter. MGMT pro-
moter methylation silences MGMT gene expression 
and this sensitizes glioma cells to TMZ (32). However, 
data from our studies and others showed the lack of 
MGMT methylation in some cell lines including 
U87-MG (31,32), suggesting the downregulation of 
methylation activity, which supports our findings. 
Furthermore, the protein data showed that the HSP70 
protein was inhibited on treatment with TMZ, 
17-AAG and VER by 13, 0 and 20 %, respectively, 
while HSP90 protein was inhibited by 84, 43 and 65 %, 
respectively, clearly highlighting the affinity of these 
three compounds towards HSP90 compared to 
HSP70. TMZ and VER showed better inhibition of 
HSP90 and 70 than 17-AAG, which could suggest that 
TMZ may share some pathways with the chaperones. 
Conclusion 
Previously we reported that RNAi mediated 
hsp90α knockdown in combination with 17-AAG 
showed a therapeutic value for glioma in vitro and in 
vivo. However, further proteomic studies from our 
laboratory and others showed that downregulating 
HSP90 protein was compensated by the induction of 
the cochaperone HSP70 protein. Here, 17-AAG was 
used to selectively inhibit HSP90 activity, while VER 
was used to dual inhibit HSP70 and 90. The overall 
expression inhibitory effects of 17-AAG and VER 
were compared to the standard glioma treatment 
TMZ using miRNA profiling. 
The novel findings of this study indicate that 
miRNA profiling showed minimum variation be-
tween 17-AAG treated and untreated U87-MG cells 
and some overlap between treatments, which was 
rather surprising because 17-AAG and VER share 
common antichaperone inhibitory activities with 
some variation in selectivity. Furthermore, Akt ki-
nase, HSP70 and 90 protein levels were found to be 
higher in 17-AAG treated cells than VER and TMZ 
treated cells suggesting less inhibition of the chaper-
one activity. This agrees with our previous findings 
that HSP70 compensates for the inhibited activity of 
HSP90. 
 Unexpectedly, VER and TMZ show greater in-
hibition of Akt kinase, HSP70 and 90 protein levels 
and shares 13 upregulated miRNAs, suggesting a 
similarity in the mode of action. However, VER may 
be a better therapeutic alternative to TMZ due to its 
potent activity with a lower IC50 and selectivity to 
cancer cells only due to the induced chaperone activ-
ity, reducing the toxic side effects. 
Future investigations to include the use of glio-
ma and other primary cancer cells are required in 
order to evaluate VER as a strong chaperone inhibitor 
and a therapeutic agent. 
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